Skip to content
Showing 51 - 60 of 78 results.
There is now a worldwide race to develop, manufacture and buy Covid-19 vaccines even before any of them have proved to be effective. Dr. David Ho is interviewed by Ms. Yvonne Tong from RTHK.
Adimmune begins phase I trial of COVID-19 vaccine in October and phase II trial in December 2020.
The United States is now looked upon by countries in Europe with incredulity and alarm as the pandemic continues rage with the US leading the world in cases and deaths.
Regeneron, Eli Lily, and Astra Zeneca are among a number of major pharmaceutical companies testing neutralizing antibody cocktails to treat and prevent SARS-CoV-2 infection.
Dr. David Ho joins Meg Tirrell on CNBC’s “Healthy Returns: The Path Forward”. He discusses the SARS-CoV-2 pandemic and the work of his research team at the Aaron Diamond Aids Research Center.
A study recently published in Nature by Dr. David Ho and his team at Columbia University identified a mix of 19 different antibodies that target SARS-CoV-2, the coronavirus that causes COVID-19.
A panel of experts summarize advances in treatments and preventative strategies to address the SARS-CoV-2 pandemic and shre views on the dire situation in the US during the surge in infections.
In an interview with MSNBC’s Rachel Maddow, Dr. David Ho discussed new research into using antibodies from COVID-19 survivors in developing a treatment or vaccine against new coronavirus infections.
Dr. David Ho laid out two theoretical strategies and outcomes in early April 2020 to address the SARS-CoV-2 pandemic in the USA.
Researchers have identified a potent cocktail of antibodies that may help doctors treat Covid-19 infections and protect people at risk from falling ill with the disease.